Disease · MONDO_0008170

ovarian cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ovarian cancer. Diseases, record MONDO_0008170. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008170

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ovarian cancer; Open Targets
Open Targets ID: MONDO_0008170; Open Targets
Other names: cancer of ovary, cancer of the ovary, malignant neoplasm of ovary, malignant neoplasm of the ovary, malignant ovarian neoplasm, malignant ovarian tumor, malignant ovarian tumour, malignant ovary neoplasm, malignant tumor of ovary, malignant tumor of the ovary, malignant tumour of ovary, malignant tumour of the ovary, ovarian cancer, somatic, ovarian malignant tumor, ovarian malignant tumour, ovary cancer; Open Targets
Disease Ontology: DOID:2394; Disease Ontology
MeSH: D010051; MeSH
NCI Thesaurus: C7431; NCI Thesaurus
Orphanet: ORPHA:213500; Orphanet
Highest stage of its drugs: Approval, for 17 of its 567 drugs, from ClinicalTrials.gov, DailyMed, PMDA and TTD; Open Targets

Drugs567

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBOPLATIN	CHEMBL1351	Small molecule	Approval	TTD	215	214	213	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Approval	DailyMed, PMDA and TTD	87	84	84	Drugs and targets
NIRAPARIB	CHEMBL1094636	Small molecule	Approval	ClinicalTrials.gov	71	70	70	Drugs and targets
TOPOTECAN	CHEMBL84	Small molecule	Approval	TTD	45	44	43	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	DailyMed	42	40	21	Drugs and targets
RUCAPARIB	CHEMBL1173055	Small molecule	Approval	TTD	15	14	14	Drugs and targets
MIRVETUXIMAB SORAVTANSINE	CHEMBL3545132	Antibody drug conjugate	Approval	TTD	13	12	12	Drugs and targets
TOPOTECAN HYDROCHLORIDE	CHEMBL1607	Small molecule	Approval	DailyMed	12	11	11	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Approval	DailyMed	10	9	9	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	TTD	4	3	3	Drugs and targets

1 to 10 of 567

See all 567 drugs

Targets424

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	24	Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 424

See all 424 targets

Trials1,149

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 32 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01015118	LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer	Phase 3	1,366	2015-01-15	Ovarian Neoplasms, Peritoneal Neoplasms	CARBOPLATIN, NINTEDANIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03038100	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 3	1,301	2023-02-17	Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms	ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors	Phase 1/2	1,163	2020-03-24	Advanced or Metastatic Solid Tumors	COBIMETINIB, IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00849667	Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse	Phase 3	1,100	2022-12-30	Ovarian Cancer	CARBOPLATIN, FARLETUZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03522246	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy	Phase 3	1,097	2025-06-24	Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response	NIVOLUMAB, RUCAPARIB	Its record names the disease	ClinicalTrials.gov
NCT02655016	A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy	Phase 3	733	2020-06-11	Ovarian Neoplasms	NIRAPARIB	Its record names the disease	ClinicalTrials.gov
NCT00940225	Study of Cabozantinib (XL184) in Adults With Advanced Malignancies	Phase 2	730	2024-04-25	Solid Tumors, Cancer	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT00113607	An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer	Phase 3	672	2013-08-23	Ovarian Cancer	DOXORUBICIN, TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT05116189	Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	Phase 3	643	2026-03-09	Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	BEVACIZUMAB, PACLITAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03797326	Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)	Phase 2	611	2025-11-17	Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer	LENVATINIB, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 1,149

See all 1,149 trials

Comparisons in its trials178

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Nintedanib vs Placebo: serious adverse events	379 of 902	157 of 450	1,352	NCT01015118	Trial comparisons
Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: deaths from any cause	272 of 651	289 of 650	1,301	NCT03038100	Trial comparisons
Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: serious adverse events	304 of 642	215 of 644	1,286	NCT03038100	Trial comparisons
Niraparib vs Placebo: deaths from any cause	48 of 484	31 of 244	728	NCT02655016	Trial comparisons
Niraparib vs Placebo: serious adverse events	156 of 484	32 of 244	728	NCT02655016	Trial comparisons
Trabectedin/DOXIL vs DOXIL: serious adverse events	133 of 333	102 of 330	663	NCT00113607	Trial comparisons
Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: deaths from any cause	225 of 322	244 of 321	643	NCT05116189	Trial comparisons
Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: serious adverse events	178 of 320	122 of 318	638	NCT05116189	Trial comparisons
Rucaparib 600 mg Tablets vs Placebo Tablets: deaths from any cause	9 of 372	2 of 189	561	NCT01968213	Trial comparisons
Rucaparib 600 mg Tablets vs Placebo Tablets: serious adverse events	91 of 372	20 of 189	561	NCT01968213	Trial comparisons

1 to 10 of 178

See all 178 comparisons in its trials

Papers from its trials741

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42225005	RESULT	1	PubMed
41747221	RESULT	1	PubMed
41528970	RESULT	1	PubMed
41389341	RESULT	1	PubMed
40762544	RESULT	1	PubMed
39792482	RESULT	1	PubMed
39151421	RESULT	1	PubMed
39031824	RESULT	1	PubMed
38718741	RESULT	1	PubMed
38471508	RESULT	1	PubMed

1 to 10 of 741

See all 741 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008170

GET https://conductscience.org/api/diseases/v1/MONDO_0008170/drugs?page=2

API reference For AI assistants